We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 29, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lilly and Co. (LLY - Free Report) , Oracle Corp. (ORCL - Free Report) , The Procter & Gamble Co. (PG - Free Report) and Comstock Holding Companies, Inc. (CHCI - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Eli Lilly, Oracle and Procter & Gamble
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Oracle Corp., and The Procter & Gamble Co., as well as a micro-cap stock, Comstock Holding Companies, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Eli Lilly have declined -4.7% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry's decline of -0.6%. Declining sales of Trulicity, rising pricing pressure on some drugs, and potential competition in the GLP-1 diabetes/obesity market are some of Eli Lilly's top-line headwinds. Lilly is making rapid pipeline progress in obesity and diabetes. However, data from phase III studies on its weight-loss pill, orforglipron, was mixed.
However, demand for popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them Lilly's key top-line drivers. Launches of these drugs in new international markets and improved supply from ramped-up production led to strong sales in the first half of 2025.
Oracle's shares have outperformed the Zacks Computer – Software industry over the year-to-date period (+43.2% vs. +16.3%). Oracle is benefiting from continued momentum from its Oracle Cloud Infrastructure business, including from winning cloud-computing contracts from AI-focused startups. ORCL's continued investment in cloud infrastructure, comprising NetSuite Enterprise Resource Planning (ERP) and Fusion ERP, positions it well for sustained growth in the dynamic software industry.
Oracle's partnership with Amazon for Oracle Database@AWS and the general availability of Oracle Database@Google bode well. Oracle's Gen 2 Cloud is driving artificial intelligence clientele. The company's share buybacks and dividend policy are noteworthy.
Shares of Procter & Gamble have declined -6.4% over the year-to-date period against the Zacks Consumer Products - Staples industry's decline of -4.0%. Procter & Gamble's elevated commodity costs, tariff pressures, higher interest expenses, and a fragile recovery in China continue to weigh on margins, earnings visibility, and overall growth momentum.
However, Procter & Gamble's strong portfolio, innovation pipeline, and disciplined productivity efforts reinforce its ability to deliver sustainable growth. Procter & Gamble's consistent execution positions it well to balance growth, resilience, and shareholder value creation.
Comstock's shares have outperformed the Zacks Building Products - Home Builders industry over the year-to-date period (+126.7% vs. +4.7%). Comstock benefits from stable, recurring revenue from asset management agreements extending through 2035, featuring cost-plus structures and performance incentives. Its debt-free, asset-light model enhances financial flexibility, while consistent revenue growth — 18.8% YoY in Q1 2025 — and expanding profitability demonstrate strong operational leverage.
However, risks include revenue concentration with a related party, low third-party diversification, and deferred incentive fee recognition. Regulatory headwinds and heavy geographic concentration in the D.C. metro area pose additional exposure.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies
For Immediate Release
Chicago, IL – August 29, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lilly and Co. (LLY - Free Report) , Oracle Corp. (ORCL - Free Report) , The Procter & Gamble Co. (PG - Free Report) and Comstock Holding Companies, Inc. (CHCI - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
To p Stock Reports for Eli Lilly, Oracle and Procter & Gamble
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Oracle Corp., and The Procter & Gamble Co., as well as a micro-cap stock, Comstock Holding Companies, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Big Morning for Q2 Numbers: GDP +3.3%, Earnings Beats for Retailers
Today's Featured Research Reports
Shares of Eli Lilly have declined -4.7% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry's decline of -0.6%. Declining sales of Trulicity, rising pricing pressure on some drugs, and potential competition in the GLP-1 diabetes/obesity market are some of Eli Lilly's top-line headwinds. Lilly is making rapid pipeline progress in obesity and diabetes. However, data from phase III studies on its weight-loss pill, orforglipron, was mixed.
However, demand for popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them Lilly's key top-line drivers. Launches of these drugs in new international markets and improved supply from ramped-up production led to strong sales in the first half of 2025.
(You can read the full research report on Eli Lilly here >>>)
Oracle's shares have outperformed the Zacks Computer – Software industry over the year-to-date period (+43.2% vs. +16.3%). Oracle is benefiting from continued momentum from its Oracle Cloud Infrastructure business, including from winning cloud-computing contracts from AI-focused startups. ORCL's continued investment in cloud infrastructure, comprising NetSuite Enterprise Resource Planning (ERP) and Fusion ERP, positions it well for sustained growth in the dynamic software industry.
Oracle's partnership with Amazon for Oracle Database@AWS and the general availability of Oracle Database@Google bode well. Oracle's Gen 2 Cloud is driving artificial intelligence clientele. The company's share buybacks and dividend policy are noteworthy.
(You can read the full research report on Oracle here >>>)
Shares of Procter & Gamble have declined -6.4% over the year-to-date period against the Zacks Consumer Products - Staples industry's decline of -4.0%. Procter & Gamble's elevated commodity costs, tariff pressures, higher interest expenses, and a fragile recovery in China continue to weigh on margins, earnings visibility, and overall growth momentum.
However, Procter & Gamble's strong portfolio, innovation pipeline, and disciplined productivity efforts reinforce its ability to deliver sustainable growth. Procter & Gamble's consistent execution positions it well to balance growth, resilience, and shareholder value creation.
(You can read the full research report on Procter & Gamble here >>>)
Comstock's shares have outperformed the Zacks Building Products - Home Builders industry over the year-to-date period (+126.7% vs. +4.7%). Comstock benefits from stable, recurring revenue from asset management agreements extending through 2035, featuring cost-plus structures and performance incentives. Its debt-free, asset-light model enhances financial flexibility, while consistent revenue growth — 18.8% YoY in Q1 2025 — and expanding profitability demonstrate strong operational leverage.
However, risks include revenue concentration with a related party, low third-party diversification, and deferred incentive fee recognition. Regulatory headwinds and heavy geographic concentration in the D.C. metro area pose additional exposure.
(You can read the full research report on Comstock here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.